← board
ANAB
AnaptysBio, Inc.distress 2/10 · well-funded / low risk$51.89-1%today-26% from 52w high
Immunology / Inflammation 1
Lead: dMMR/MSI-H resectable colon cancer
Revenue
$26M
Liquidity
$248M
Runway
—
Shares 1y
+4%
Price & events
+64.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-4.2%
1W
-12.7%
1M
+1.2%
3M
+63.7%
6M
+188.3%
1Y
+110.6%
2Y
+202.3%
5Y
+233.2%
All
Overview
- Market Cap
- $1.51B
- Volume
- 64.84K
- 52 Week Range
- $12.93 – $69.81
- Total Shares
- 29.10M
- Float Shares
- 19.79M
- Short %
- 38.70%
- % Held by Insiders
- 5.68%
- % Held by Institutions
- 102.39%
- RVOL
- 0.09x
- Beta
- 0.38
Pipeline stages · 1 programs
Rosnilimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01 | Phase 2 | Rosnilimab | Ulcerative Colitis | 132 | active not recruiting |
Catalyst news & presentations · 6
- 2028Guided 40%readoutPhase 3dostarlimab · Top-line data expectedSEC 8-K
- 2026Guided 40%readoutPhase 2dostarlimab · Top-line data expectedSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-03-26partnershipPrivate placement of SpinCo common stock with EcoR1 Capital and investors for ~$80M gross proceeds.SEC 8-K
- January 11, 2026conferencedata presentationsecondaryPresentation at 2026 J.P. Morgan Healthcare Conference disclosing preliminary financial resultsSEC 8-K
- 2025-09-29partnershipBoard approved plans to explore separating into two independent public companies by end of 2026SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $87 (+68% upside) · 11 analysts
- 2026-05-13BarclaysOverweight
- 2026-05-13UBSBuy
- 2026-05-04Piper SandlerOverweight
- 2026-04-28Leerink PartnersOutperform
- 2026-04-22BarclaysOverweight
- 2026-04-21UBSBuy
Competitors — dMMR/MSI-H resectable colon cancer
- none identified
Recent news
- 2026-07-20AnaptysBio (NASDAQ:ANAB) Shares Down 6.2% - Here's Why - MarketBeat
- 2026-07-17AnaptysBio (NASDAQ:ANAB) Trading 5.3% Higher - Should You Buy? - MarketBeat
- 2026-07-16Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
- 2026-07-15AnaptysBio (NASDAQ:ANAB) Shares Gap Down - What's Next? - MarketBeat
- 2026-07-15Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
- 2026-07-15Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
- 2026-07-15Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
- 2026-07-15A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.